Study of drugs Targeting Mitogen-Activated Protein Kinase Pathway in Gastrointestinal Cancer
What is the Purpose of this Study?
If you choose to join this study, you will:
- Take the study drug (ERAS-007) in combination with other drugs, which will depend on the type of mutations your cancer has
- Have blood draws
- Give urine samples
- Have regular CT or MRI scans
- Have other tests done during your clinic visits
- Take the study drug (ERAS-007) in combination with other drugs, which will depend on the type of mutations your cancer has
- Have blood draws
- Give urine samples
- Have regular CT or MRI scans
- Have other tests done during your clinic visits
What is the Condition Being Studied?
Colorectal Cancer and Pancreatic Cancer
Who Can Participate in this Study?
Adults with colorectal cancer who:
- Have KRAS or NRAS mutations
- Able to swallow oral medication.
- Do not have a history of HIV infection, hepatitis B virus, or hepatitis C virus.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to see if an experimental drug called ERAS-007 is a safe and effective treatment for your cancer when given in combination with other cancer therapies.
Study Details
Full Title
[ERAS-007-03] A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Principal Investigator
Protocol Number
IRB:
PRO00108782
NCT:
NCT05039177
ClinicalTrials.gov
View on ClinicalTrials.gov